Generics
InvaGen wins final approval for generic Lyrica in 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg
22 July 2019 -

Pharmaceutical company InvaGen Pharmaceuticals Inc reported on Monday that it has received the final approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules in 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg .

Available immediately, Pregabalin Capsules are AB-rated and the generic therapeutic equivalent version of Pfizer's Lyrica.

The company added that Pregabalin capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, as well as fibromyalgia, along with management of neuropathic pain associated with spinal cord injury

According to IQVIA (IMS Health), Lyrica had US sales of approximately USD5.4bnn for the 12-month period ending March 2019, concluded the company.

Login
Username:

Password: